Publication:
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.

Simple item page
dc.contributor.authorDíez-Campelo, María
dc.contributor.authorLorenzo, Jose I
dc.contributor.authorItzykson, Raphael
dc.contributor.authorRojas, Silvia M
dc.contributor.authorBerthon, Céline
dc.contributor.authorLuño, Elisa
dc.contributor.authorBeyne-Rauzy, Odile
dc.contributor.authorPerez-Oteyza, Jaime
dc.contributor.authorVey, Norbert
dc.contributor.authorBargay, Joan
dc.contributor.authorPark, Sophie
dc.contributor.authorCedena, Teresa
dc.contributor.authorBordessoule, Dominique
dc.contributor.authorMuñoz, Juan A
dc.contributor.authorGyan, Emmanuel
dc.contributor.authorSuch, Esperanza
dc.contributor.authorVisanica, Sorin
dc.contributor.authorLópez-Cadenas, Félix
dc.contributor.authorde Botton, Stéphane
dc.contributor.authorHernández-Rivas, Jesús M
dc.contributor.authorAme, Shanti
dc.contributor.authorStamatoullas, Aspasia
dc.contributor.authorDelaunay, Jacques
dc.contributor.authorSalanoubat, Celia
dc.contributor.authorIsnard, Françoise
dc.contributor.authorGuieze, Romain
dc.contributor.authorPérez Guallar, Joan
dc.contributor.authorBadiella, Llorenc
dc.contributor.authorSanz, Guillermo
dc.contributor.authorCañizo, Consuelo
dc.contributor.authorFenaux, Pierre
dc.date.accessioned2023-01-25T10:06:01Z
dc.date.available2023-01-25T10:06:01Z
dc.date.issued2018-04-02
dc.description.abstractTreatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P 
dc.identifier.doi10.1111/bjh.15190
dc.identifier.essn1365-2141
dc.identifier.pmid29611196
dc.identifier.unpaywallURLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.15190
dc.identifier.urihttp://hdl.handle.net/10668/12302
dc.issue.number3
dc.journal.titleBritish journal of haematology
dc.journal.titleabbreviationBr J Haematol
dc.language.isoen
dc.organizationHospital Universitario Puerta del Mar
dc.page.number350-359
dc.pubmedtypeClinical Trial
dc.pubmedtypeComparative Study
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectazacitidine
dc.subjectchromosome 7 abnormalities
dc.subjecthigh risk MDS
dc.subjecttime-dependent analysis
dc.subject.meshAged
dc.subject.meshAzacitidine
dc.subject.meshChromosome Aberrations
dc.subject.meshChromosomes, Human, Pair 7
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMyelodysplastic Syndromes
dc.subject.meshRegistries
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Factors
dc.subject.meshSurvival Rate
dc.titleAzacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number181
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Puerta del Mar

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía